Drug Type Small molecule drug |
Synonyms Agileo, Instant release (IR) tolperisone tablets - Sanochemia, Sustained release tolperisone tablets - Sanochemia + [13] |
Target |
Mechanism SCNA blockers(Sodium channel alpha subunit blockers), VDCCs blockers(Voltage-gated calcium channel blockers) |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CH (24 Aug 1966), |
Regulation- |
Molecular FormulaC16H24ClNO |
InChIKeyZBUVYROEHQQAKL-UHFFFAOYSA-N |
CAS Registry3644-61-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01507 | Tolperisone Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cardiovascular Diseases | CN | 01 Jan 1986 | |
Muscle Spasticity | CH | 24 Aug 1966 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Pain | Phase 3 | US | 15 Dec 2020 | |
Back Pain | Phase 3 | US | 15 Dec 2020 | |
Lordosis | Phase 3 | US | 15 Dec 2020 | |
Spasm | Phase 3 | US | 15 Dec 2020 | |
Multiple Sclerosis | Phase 3 | UA | 01 Sep 2007 | |
Multiple Sclerosis | Phase 3 | RU | 01 Sep 2007 | |
Multiple Sclerosis | Phase 3 | RS | 01 Sep 2007 | |
Spinal Cord Injuries | Phase 3 | CA | 01 Sep 2007 | |
Spinal Cord Injuries | Phase 3 | US | 01 Sep 2007 | |
Muscle Spasticity | Phase 3 | CZ | - |
Phase 3 | 1,004 | (ypwpfplpos) = failed to meet its primary endpoints dqyboqkegq (uwfuksfmbm ) | Positive | 22 Mar 2022 | |||
Phase 2 | 415 | (Tolperisone 50 mg) | nxxkhcdegw(zrouvabpns) = bosankplkw irdonuyzwi (tafkvuypef, fqbpkwhiwd - ykskyjibnh) View more | - | 10 Nov 2020 | ||
(Tolperisone 100 mg) | nxxkhcdegw(zrouvabpns) = ocbvadhbmu irdonuyzwi (tafkvuypef, vedxhlvols - huhxfxdeyy) View more |